solifenacin succinate has been researched along with Recrudescence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TC; Hsiao, SM; Lin, HH | 1 |
| Chang, TC; Chen, CH; Hsiao, SM; Lin, HH; Wu, WY | 1 |
1 trial(s) available for solifenacin succinate and Recrudescence
| Article | Year |
|---|---|
The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study.
Topics: Aged; Drug Administration Schedule; Female; Humans; Middle Aged; Muscarinic Antagonists; Recurrence; Retreatment; Solifenacin Succinate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
1 other study(ies) available for solifenacin succinate and Recrudescence
| Article | Year |
|---|---|
Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder.
Topics: Adult; Aged; Biomarkers; Creatinine; Female; Humans; Middle Aged; Muscarinic Antagonists; Nerve Growth Factor; Nocturia; Proportional Hazards Models; Prospective Studies; Recurrence; ROC Curve; Solifenacin Succinate; Urinary Bladder; Urinary Bladder, Overactive | 2017 |